隶属于 Moderna
American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, focused on RNA therapeutics, primarily mRNA vaccines; has commercial vaccines for COVID-19, RSV, and influenza, with dozens of additional candidates in development.
相关临床试验
159
45 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2010
进行中（未招募）
42
26.4%
已完成
79
49.7%
尚未招募
3
1.9%
招募中
25
15.7%
终止
6
3.8%
Unknown
1
0.6%
撤回
3
1.9%
暂无批准数据
- Novartis's pelacarsen and Novo Nordisk's ziltivekimab both failed to separate from placebo in late-stage cardiovascular outcome trials despite strong genetic support for their targets. - Cardiologist Ethan Weiss said the field can no longer claim that genetics is undefeated in predicting which drugs will work in outcome studies. - Novartis shares fell 14% in a single session and Amgen dropped 9.8% as investors repriced roughly 35,000 patients still enrolled in Lp(a) outcome trials. - Weiss attributed the Lp(a) failure largely to background therapy, arguing the risk signal diminishes in patients already on statins and other powerful medicines.
- At the TIME100 Health Leadership Forum in New York, oncology experts named vaccines, immunotherapy, early detection and prevention as the most promising fronts in cancer research. - American Cancer Society CEO Shane Jacobson credited philanthropic and federal funding for rapid innovation, citing Moderna and Merck's encouraging mRNA cancer vaccine results. - Memorial Sloan Kettering oncologist Andrea Cercek cited a 2024 rectal cancer study in which no patient had detectable tumors after six months of immunotherapy. - Cercek said she is 'very close' to extending this immunotherapy approach to other cancers, and predicted early detection and prevention will ultimately cure cancer.
- The US FDA has approved Moderna's mRNA-based seasonal influenza vaccine mFlusiva for people aged 50 to 64, the first flu vaccine using mRNA production. - mFlusiva encodes full-length viral hemagglutinin surface glycoproteins from three WHO-recommended influenza strains, delivered by lipid nanoparticles into cells. - In two clinical trials, mFlusiva outperformed GlaxoSmithKline's four-strain Fluarix in preventing influenza infection or eliciting antibody responses.
- Merck is building its next growth phase around a phase III pipeline that has nearly tripled since 2021 and a target of 20 new drug launches by 2030. - The company projects more than $70 billion in non-risk-adjusted commercial opportunity from its current pipeline by the mid-2030s, more than double Keytruda's $35 billion peak consensus estimate. - Merck and Moderna reported the first positive phase 3 result for a personalized mRNA cancer vaccine, though detailed efficacy and overall survival data remain pending. - Management expects the Keytruda loss-of-exclusivity period to resemble a shallow dip or hill with a quick return to growth rather than a revenue cliff.
- BioNTech and Genentech terminated the Phase II BNT122-01 trial of autogene cevumeran in resected colorectal cancer after a DSMB found an overall survival imbalance favoring the control arm. - The DSMB had previously flagged futility in October 2025 but allowed the trial to continue, concluding the data were too immature for reliable efficacy conclusions. - No new safety signals were identified, and the pancreatic cancer program IMcode003 testing autogene cevumeran with atezolizumab and mFOLFIRINOX continues as planned. - The result reinforces questions about personalized mRNA vaccines in immunologically cold, microsatellite stable tumors without checkpoint inhibitor support.
- An Army doctor testified in federal court that she is examining 2,544 unverified deaths among service members reported to HHS's Vaccine Adverse Event Reporting System (VAERS). - Theresa Long, senior medical military adviser to Health Secretary Robert F. Kennedy Jr., said she knows of 28 people who died from the COVID-19 vaccine but was not permitted to share more details. - Long's Aug. 14 deposition, obtained by Politico, came in a lawsuit over the CIA's dismissal of Terry Adirim, who alleges she was fired for her advocacy of COVID-19 vaccination. - The testimony highlights ongoing scrutiny of COVID-19 vaccine safety, though a 2022 study found 38 deaths could have been related to the vaccine after more than 8 billion doses were administered.
- South Korean and U.S. healthcare experts urged regulatory reforms aligned with global standards to support sustainable growth and improve patient care at an AMCHAM seminar in Seoul. - Local doctors emphasized that precision diagnostics and treatment, including genome testing for advanced lung cancer patients, are urgently needed but currently hindered by regulatory barriers. - Experts called for legislation specifically addressing corneal transplants, noting that access is restricted by regulations treating corneas like other human tissue. - The government pledged to shorten reimbursement approval times for rare disease treatments and strengthen outcomes-based value assessments.
- Australia is vaccinating 5,000 little penguins on Phillip Island against H5N1 using the Zoetis H5N2-subtype killed-virus vaccine, not an mRNA product. - Veterinary and agriculture officials confirmed the inactivated vaccine contains no live virus and cannot cause disease or replicate in recipients. - The unprecedented rollout follows Australia's first H5N1 detection in June 2026 and 484 confirmed H5 wildlife events as of September 4. - Vaccine scientists say no scientific data supports claims that mRNA vaccines are inherently harmful or capable of altering a recipient's genome.
- Pfizer and Valneva have completed a 9,000-participant Lyme vaccine trial showing 73.2 to 74.8 percent efficacy with no safety concerns, and are preparing an FDA submission. - The vaccine missed its primary statistical goal, though Pfizer called the reduction in infections clinically meaningful; results will be presented at a scientific congress. - A March court injunction bars the 13 ACIP members appointed in 2025 from meeting or issuing new vaccine recommendations, leaving the Lyme rollout pathway undefined. - Without ACIP guidance, insurance coverage and Vaccines for Children Program access are uncertain, and medical societies are issuing patchwork recommendations in its place.
- Dolly Parton told her sister Stella that if there was "no hope" in her cancer battle, she would still allow her medical team to try experimental drugs to help others in the future. - Stella Parton revealed the request in an emotional Facebook tribute following the country music icon's death after a brief battle with cancer at age 80. - The late icon was admitted to a Nashville hospital late last week after dealing with kidney and autoimmune issues, according to her sister. - Parton's lifetime of philanthropy included a $1 million donation to Vanderbilt University's COVID-19 research that contributed to the development of the Moderna vaccine.
